Today's Trend
Aptevo Therapeutics Inc. (APVO) saw its stock price increase amid a wave of positive clinical updates and heightened trading activity. Investors cheered new data on mipletamig, the company’s lead bispecific antibody candidate for acute myeloid leukemia (AML), while trading was punctuated by multiple regulatory halts and an at-the-market equity offering.
- New Phase 1b/2 RAINIER trial data showed an 85% remission rate in frontline AML patients treated with mipletamig plus venetoclax/azacitidine, with no dose-limiting toxicities reported (Access Newswire, 7:01 AM, 6/18/25).
- Favorable results in an acute leukemia study led to shares more than doubling after the company reported strong efficacy for its lead drug candidate (MarketWatch, 2:03 PM, 6/18/25).
- Aptevo’s stock surged following publication of investigational drug trial data for aggressive blood cancer, highlighting potentially transformational activity of mipletamig (Benzinga, 11:03 AM, 6/18/25).
- Impressive AML treatment results prompted analysts and traders to push the stock higher, with premarket trading seeing a significant “skyrocket” (Investing.com & Tokenist, 6/18/25).
- Trading was temporarily halted several times due to LULD pauses as volatility spiked during the flow of clinical news (multiple halts on 6/18/25).
- A new interactive stock chart was made available on Barron’s, reflecting increased investor interest (Barron’s, 6/19/25).
- Aptevo announced an $8 million at-the-market equity offering at $3.25 per share, including warrants for up to 12.3 million shares—raising capital but diluting existing equity (Access Newswire, 9:52 AM, 6/18/25).